Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 08:03 am
Share
Daewon Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 29.32 million compared to KRW 3.43 million a year ago. Net income was KRW 6,272.28 million compared to KRW 3,499.16 million a year ago. Basic earnings per share from continuing operations was KRW 295.1456 compared to KRW 164.0777 a year ago. Basic earnings per share was KRW 295.1456 compared to KRW 164.0777 a year ago.
For the nine months, sales was KRW 58.66 million compared to KRW 37.65 million a year ago. Net income was KRW 1,240.08 million compared to KRW 15,449.88 million a year ago. Basic earnings per share from continuing operations was KRW 58.2524 compared to KRW 722.3301 a year ago. Basic earnings per share was KRW 58.2524 compared to KRW 722.3301 a year ago.
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
DAEWON PHARMACEUTICAL CO., LTD. 
